Closed · RFA-FD-14-024 · CFDA 93.103 · Discretionary

Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs (U01)

Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.

$750K-$1M
Award range
Closed
Status
June 2, 2014
Close date
1
Expected awards

The verdict

Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs (U01) is a closed discretionary listing from Food and Drug Administration that offered $750,000 -- $1,000,000 across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.

$750K-$1M
award range
Closed
application status
1
expected award
93.103
CFDA program

Archived opportunity record

Pharmacokinetic and Pharmacodynamic is closed (last close June 2, 2014). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed June 2, 2014

Posted Apr 18 Closes Jun 2

Est. Total Funding

$3,000,000

Expected Awards

1

Instrument

Cooperative Agreement

Description

Background: Metoprolol is a selective β1 receptor blocker used in treatment of several cardiovascular diseases, especially hypertension. Metoprolol is metabolized primarily by the cytochrome P450 isoform CYP2D6, which is subject to a genetic polymorphism. It has been formulated in different salt forms including tartrate, fumarate, and succinate salts, as well as different dosage forms such as immediate release and, extended release products. Different metoprolol drug products showed different pH-dependent drug release characteristics which seem to be consistent with the observed PK profile differences. The US FDA currently recommends single dose bioequivalence studies in healthy subjects to establish the bioequivalence of generic metoprolol products with their corresponding reference listed drug (RLD) based on 90% confidence interval of Cmax and AUC within 80.00-125.00%. The same bioequivalence criteria apply to any post approval changes of brand products which require in-vivo bioequivalence studies. Therapeutic inefficacy and adverse events have been reported by physicians and patients switching from brand to generic metoprolol extended release products. The FDA continues to monitor the FDA Adverse Event Reporting System (FAERS) for reports relating to currently marketed metoprolol products. However, based on current data available to the agency, it is difficult to draw definitive conclusions about the cause of the concern. Therefore, PK/PD studies in patient population are needed to help address the potential bioequivalence and therapeutic equivalence issues with metoprolol products. Objectives: The objectives of this project are to conduct a prospective PK/PD study in hypertensive patients to link the PK profiles to the time-course of PD activity of metoprolol, therefore, to identify the key product attributes and patient factors that may impact the therapeutic equivalence of metoprolol products. The specific objectives of the study were to: 1) Evaluate the PK-PD relationship; 2) Evaluate the effect of treatment (before and after switching metoprolol products) on the PK-PD relationship; 3) Evaluate the effect of pH variation in the population and rate of delivery on the PK-PD relationship; 4) Evaluate the effect of CYP2D6 phenotype on the PK-PD relationship; Detailed Description: Additional details regarding the study objectives are listed below: A prospective, randomized crossover trial design is suggested, i.e., switching over to a different metoprolol product at the same dose level as the prior one. The study should use a combination of products having different shapes of PK profiles. Simultaneous collections of PK and PD samples (before and after switch) at steady state are recommended to link PK profiles to PD effect. The selection of appropriate PD endpoint(s) has to be well justified. The study should enroll CYP2D6 extensive and poor metabolizers to assess the CYP2D6 phenotype impact on the PK profiles and PD activity of metoprolol extended release tablets. The study should evaluate the pH variations of the population and its impact on the PK profiles and PD effect of metoprolol extended release tablets. The focus of the first year is to develop a study protocol for FDA Research in Human Subject Committee (RIHSC) and investigator Institution Research Board (IRB) approval, product blinding, quality testing, bioanalytical method validation, and patient enrollment.

Wide-open applicant board · 15 Grants.gov doors

Pharmacokinetic and Pharmacodynamic prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Health · Science and Technology / R&D (HL;ST). 120 other Food and Drug Administration listings share this eligibility-code string (25% of 482).

Code 00
State governments
Code 01
County governments
Code 02
City or township governments
Code 04
Special district governments
Code 05
Independent school districts
Code 06
Public / state-controlled institutions of higher education
Code 07
Federally recognized tribal governments
Code 08
Public / Indian housing authorities
Code 11
Native American tribal organizations (other than Federally recognized tribal governments)
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education
Code 22
For-profit organizations other than small businesses
Code 23
Small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

Gladys Melendez-Bohler Grants Management Officer/Specialist Phone 240-402-7565

What to do next

Pharmacokinetic and Pharmacodynamic is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
  • Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
  • Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants